RECRUITING

EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures

Conditions

Ureteral Stricture ureteral ureteric stricture stenosis optilume

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main objective of this clinical investigation is to assess the safety and feasibility of the Optilume DCB for treatment of ureteric strictures.

Official Title

EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures

Quick Facts

Study Start:2025-09-30

Study Completion:2031-07-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07020520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age 18 years or older 2. Single lesion ureteric or uretero-enteric stricture less than or equal to 4.0 cm in length 3. Two functioning kidneys	1. Treatment of the target ureter with incision or balloon dilation within 3 months of the study treatment 2. Subjects with more than one ureteric stricture 3. Subjects with target stricture in bifid or duplicated ureter 4. Known sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel 5. Ureteric stricture caused by extrinsic compression of the ureter 6. Unable to endoscopically access target stricture for any reason 7. Existing stones in the ipsilateral kidney or ureter (except for asymptomatic kidney stones) that are in close proximity to the target ureteric stricture 8. Chronic renal failure treated with dialysis 9. eGFR \<30 mL/min/1.73m2 10. Kidney function ≤ 25% of split function on the side with target stricture as measured by functional renogram 11. Kidney function ≤35% of split function on the side opposite target stricture as measured by functional renogram or other significant pathology or impairment that may impact renal function 12. Life expectancy less than 12 months 13. Women who are pregnant or breastfeeding 14. Women of child-bearing potential planning to get pregnant in the next year or are unwilling to use contraception over the next 12 months 15. Males unwilling to abstain or use protected sex for 30 days post treatment 16. Males unwilling to use highly effective contraception for6 months post treatment if sexual partner(s) are of child-bearing potential 17. Inability to provide legally effective informed consent 18. Unwilling or unable to meet protocol follow-up requirements 19. Participation in any interventional clinical investigation of a medical device, drug, or biologic (excluding registries) that may confound the results of the trial 20. Active systemic or urinary tract infection 21. Active malignancy in the abdomen or pelvis, or any malignancy considered considerable risk for metastasizing to the abdomen or pelvis over the next 12 months 22. Uncontrolled diabetes defined as hemoglobin A1C ≥ 8% at baseline 23. Unable to come off antiplatelet or anticoagulation medication prior to treatment to prevent bleeding complications at the discretion of the investigator 24. Any other condition that may confound the results of the trial or presents an unacceptable risk for any study-related procedure 25. Individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response 26. Presence of any condition that precludes administration of furosemide during renograms 27. Unable to tolerate contrast related to required study procedures or imaging.

Inclusion Criteria

Exclusion Criteria

1. Age 18 years or older
2. Single lesion ureteric or uretero-enteric stricture less than or equal to 4.0 cm in length
3. Two functioning kidneys

1. Treatment of the target ureter with incision or balloon dilation within 3 months of the study treatment
2. Subjects with more than one ureteric stricture
3. Subjects with target stricture in bifid or duplicated ureter
4. Known sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel
5. Ureteric stricture caused by extrinsic compression of the ureter
6. Unable to endoscopically access target stricture for any reason
7. Existing stones in the ipsilateral kidney or ureter (except for asymptomatic kidney stones) that are in close proximity to the target ureteric stricture
8. Chronic renal failure treated with dialysis
9. eGFR \<30 mL/min/1.73m2
10. Kidney function ≤ 25% of split function on the side with target stricture as measured by functional renogram
11. Kidney function ≤35% of split function on the side opposite target stricture as measured by functional renogram or other significant pathology or impairment that may impact renal function
12. Life expectancy less than 12 months
13. Women who are pregnant or breastfeeding
14. Women of child-bearing potential planning to get pregnant in the next year or are unwilling to use contraception over the next 12 months
15. Males unwilling to abstain or use protected sex for 30 days post treatment
16. Males unwilling to use highly effective contraception for6 months post treatment if sexual partner(s) are of child-bearing potential
17. Inability to provide legally effective informed consent
18. Unwilling or unable to meet protocol follow-up requirements
19. Participation in any interventional clinical investigation of a medical device, drug, or biologic (excluding registries) that may confound the results of the trial
20. Active systemic or urinary tract infection
21. Active malignancy in the abdomen or pelvis, or any malignancy considered considerable risk for metastasizing to the abdomen or pelvis over the next 12 months
22. Uncontrolled diabetes defined as hemoglobin A1C ≥ 8% at baseline
23. Unable to come off antiplatelet or anticoagulation medication prior to treatment to prevent bleeding complications at the discretion of the investigator
24. Any other condition that may confound the results of the trial or presents an unacceptable risk for any study-related procedure
25. Individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response
26. Presence of any condition that precludes administration of furosemide during renograms
27. Unable to tolerate contrast related to required study procedures or imaging.

Contacts and Locations

Study Contact

Steven M Principal Clinical Project Manager

CONTACT

952-426-6079

smadej@laborie.com

Reem Ennenga

CONTACT

rennenga@laborie.com

Principal Investigator

Jamie Landman, MD

PRINCIPAL_INVESTIGATOR

University of California, Irvine

Study Locations (Sites)

University of California Irvine

Orange, California, 92868

United States

Orlando Health

Orlando, Florida, 32806

United States

Collaborators and Investigators

Sponsor: Urotronic Inc.

Jamie Landman, MD, PRINCIPAL_INVESTIGATOR, University of California, Irvine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-30

Study Completion Date2031-07-30

Study Record Updates

Study Start Date2025-09-30

Study Completion Date2031-07-30

Terms related to this study

Keywords Provided by Researchers

ureteral
ureteric
stricture
stenosis
optilume

Additional Relevant MeSH Terms

Ureteral Stricture